Sep 8, 2026, 8:08 PM2 views

Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

Marketwatch Verified Source

Reported by Jaimy Lee · Syndicated via official news feed

Read Full Story on Marketwatch

Explore all Business stories

Syndicated feed content with full publisher credit.

Business Desk

More in Business

Continue reading verified coverage and related developments on this desk.

View All

BUSINESS29M AGO

Odd Lots: Why Money Launderers Love $100 Bills

On this episode of the Odd Lots podcast, journalist Oliver Bullough joins Tracy Alloway and Joe Weisenthal to discuss why criminal enterprises love to launder money in the form of $100 bills and why money laundering…

BUSINESS32M AGO

US Targets Iran’s Airlines as New Sanctions Push Continues

The US took action against dozens of firms supporting Iran’s aviation sector on Tuesday, as part of a new sanctions effort from the Trump administration that hasn’t appeared to have much impact on Tehran’s main trading…

BUSINESS33M AGO

Private Credit’s Tokenization Revolution

Apex Group CEO Peter Hughes joins Bloomberg Open Interest to explain why family offices need better access to quality private-market deals. He also makes the case that regulated tokenization could transform private…

BUSINESS37M AGO

Odd Lots: How Is Farm Equipment Used for Money Laundering?

On this episode of the Odd Lots podcast, journalist Oliver Bullough joins Tracy Alloway and Joe Weisenthal to discuss how Mexican cartels use heavy farm equipment to launder money and why criminals are always looking…

BUSINESS38M AGO

China Ships Out First Sulfuric Acid Cargo Since Halt on Exports

China has allowed its first outbound shipment of sulfuric acid since May, offering some relief to copper producers squeezed by a global shortage after the Iran war choked off Middle East supplies.

BUSINESS39M AGO

Jensen Huang’s AGI Claim Is A Business Case, Not Settled Fact

Jensen Huang says AGI has arrived, but the claim reflects AI’s business value more than proof of human-level, general-purpose intelligence.